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Abstract
A substantial body of literature concerning resuscitation from
cardiac arrest now exists. However, not surprisingly, the greater
part concerns the cardiac arrest event itself and optimising survival
and outcome at relatively proximal time points. The aim of this
review is to present the evidence base for interventions and thera-
peutic strategies that might be offered to patients surviving the
immediate aftermath of a cardiac arrest, excluding components of
resuscitation itself that may lead to benefits in long-term survival. In
addition, this paper reviews the data on long-term impact, physical
and neuropsychological, on patients and their families, revealing a
burden that is often underestimated and underappreciated. As
greater numbers of patients survive cardiac arrest, outcome
measures more sophisticated than simple survival are required.
Introduction
Survival to a particular time after an ‘index’ cardiac arrest
event, as recommended by the Utstein guidelines [1], is the
most commonly reported outcome measure for resuscitation,
with hospital discharge and 1-year survival often reported.
Excessive mortality risk is greatest within the first year after
arrest and, after 2 years, approaches that of an age- and
gender-matched population [2]. A retrospective review of in-
hospital mortality identified neurological injury as the mode of
early death in two thirds of out-of-hospital cardiac arrest
(OOHCA) patients admitted to intensive care. Cardiovascular
death and multi-organ failure death accounted for the
remainder [3]. A number of studies have investigated survival
rates at greater than 1 year and how survival following
OOHCA has changed over time. Such studies suggest that
longer-term survival figures are improving [4-7]. This may be
due to changes in coronary artery disease patterns,
resuscitation practice, and/or subsequent medical
intervention.
With greater numbers of patients now surviving for longer
periods, survival alone may be an inadequate assessment of
resuscitation and post-resuscitation care. A more suitable
tool may be assessment of quality of life (QOL) after hospital
discharge. This requires an understanding of the psycho-
social impact of cardiac arrest and its sequelae on the
survivor and associated family members.
The aim of this review is to present the evidence base for
interventions and therapeutic strategies that might be offered
to patients surviving the immediate aftermath of an OOHCA
(excluding components of resuscitation itself) which may lead
to benefits in long-term survival. In addition, this paper
reviews the data on long-term impact, both physical and
neuropsychological, on patients and their families.
Methodology
Search terms recommended by the American Heart Associa-
tion [8] and International Liaison Committee on Resuscitation
(ILCOR) were used. These were used by working parties
evaluating evidence for the ILCOR 2005 Consensus
statement [9].
An electronic search of the literature by means of PubMed
was conducted using MeSH (Medical Subject Heading) main
search terms ‘heart arrest’ or ‘cardiopulmonary resuscitation’.
Additional terms recommended were ‘antiarrhythmia agent’,
‘glucose’, ‘hypothermia’ or ‘induced hypothermia’, ‘defibril-
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lators, implantable’, ‘seizures’, ‘thrombolytic therapy’, ‘angio-
plasty’, ‘coronary artery bypass grafting’, and ‘ventricular
dysfunction’. The primary search identified a total of 4,431
papers. The following search limits were then applied: human,
adult, and English language. Application of search limits
reduced the initial search to 1,038 articles. Studies were then
reviewed for relevance. We excluded papers if they were
reviews, case reports, or referred to interventions prior to the
return of a spontaneous circulation; 58 papers were identi-
fied. Additional papers were obtained from the reference list
used by the ILCOR working parties for the 2005 Consensus
statement and from a manual search of reference lists from
reviewed papers. A total of 73 papers were identified as
relevant for inclusion.
Using the search term ‘quality of life’ and the same primary
search terms and limits, we identified 59 articles, of which 27
were relevant. A manual search of reference lists was also
conducted, leading to the inclusion of another 13 articles.
Overall, the literature retrieved was somewhat diverse and
was not suitable for meta-analysis. Specifically, papers did
not consistently report the patient populations in terms of
cause of cardiac arrest or whether they occurred in-hospital
or out-of-hospital and there was substantial heterogeneity.
Thus, the evidence was synthesised into a narrative review.
Overview of long-term mortality
Survival studies performed during the period 1970 to 1985
found a 4-year survival of 40% to 61% [6,10-12]. Investiga-
tors (from several countries) examining long-term survival of
patients discharged from the hospital following OOHCA have
consistently shown an improvement. Pell and colleagues [5]
showed that 5-year survival had improved in Scotland over a
10-year period (1991 to 2001) from 64.2% to 76%. This was
due to a reduction in the risk of subsequent cardiac death.
Part of this improvement was attributed to a higher percen-
tage of patients less than 55 years of age and changes in
clinical management after cardiac arrest. The subsequent use
of beta-blockers, angiotensin-converting enzyme (ACE)
inhibitors, antithrombotic agents, and revascularisation
methods had increased over time. The authors also identified
the increased use of implantable cardiac defibrillators (ICDs)
and changes in smoking habits as reasons for the
improvements observed [5]. Similar mortality results for
OOHCA have been observed by Cobbe and colleagues [4],
also in Scotland, for the period 1988 to 1994, with a 4-year
survival rate of 68%. Rea and colleagues [13] found that
long-term OOHCA survival in King County, WA, USA, had
improved over a 26-year study period (1976 to 2001). Over
each 5-year interval, cardiac mortality fell by 21% [13]. Again,
the authors identified changes in clinical practice and lifestyle
changes as being important. Data published from Olmstead
County, MN, USA, from 1990 to 2001 of confirmed
ventricular fibrillation (VF) cardiac arrests found a 5-year
survival rate of 79% [7]. The higher figures obtained by these
authors may reflect an enrolment bias as only patients with a
confirmed initial rhythm of VF were included.
In contrast, Engdahl and colleagues [14] have shown no
improvement in survival in a Swedish cohort between 1981
and 1998. Notable differences, when compared with data
from Scotland, include the proportion of those surviving to
hospital discharge with an initial rhythm of VF and the number
of patients receiving bystander resuscitation [5]. Pell and
colleagues [5] found that almost all (greater than 94%)
patients had an initial rhythm of VF or ventricular tachycardia
(VT) compared with approximately 80% in the Swedish
cohort. The number of patients receiving bystander
resuscitation was consistently above 60% in the Scottish
cohort compared with approximately 30% in the Swedish
study. This lends support to current European Resuscitation
Council recommendations on the need for early basic life
support [15].
Interventions
Changes in survival represent the culmination of several
medical advances that have occurred over the previous two
decades. Improvements in primary and secondary prevention
of coronary artery disease and changes in resuscitation have
all contributed. Interventions shown to improve outcome
following return of spontaneous circulation (ROSC) include
optimisation of ventricular function immediately after the
event, revascularisation, arrhythmia management, and thera-
peutic hypothermia (Table 1).
Revascularisation is integral to ventricular optimisation and
arrhythmia management and will be discussed in conjunction
with these interventions. The identification of the risk of
ventricular arrhythmias after cardiac arrest by electrophysio-
logical testing can predict long-term outcome. Thus, Wilber
and colleagues [16] examined 166 survivors of OOHCA not
associated with acute myocardial infarction (MI) and identi-
fied, over a mean follow-up of 21 months, a 33% (12/36)
cardiac arrest recurrence rate in patients with inducible, but
not suppressed, arrhythmias. This was compared with 12%
(11/91) in whom inducible arrhythmias had been suppressed
by surgery or antiarrhythmic agents [16].
Revascularisation
Cardiac arrest survivors with significant coronary athero-
sclerotic disease have a 20% chance of VF recurrence at
1 year [17-19]. Of those admitted to hospital immediately
after cardiac arrest, almost half have coronary artery
occlusion. Furukawa and colleagues [20] showed, in post-
arrest patients with chronic coronary artery disease,
ventricular arrhythmias unresponsive to therapy to be
predictive of higher 2-year mortality. Patients surviving
OOHCA often have a reversible ischaemic cause for their
cardiac arrest. Ventricular arrhythmias as a cause of cardiac
arrest often are associated with myocardial ischaemia. Bunch
and colleagues [21] identified that 78% (66/79) of VFPage 3 of 17
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fOOHCA patients surviving to hospital discharge had
ischaemic heart disease, with 47% of these presenting with
an acute MI. Similar findings have been reported from
Göteborg, Sweden, and Glasgow, Scotland [10,14].
Although there is a large body of evidence validating throm-
bolysis in patients with ST segment elevation myocardial
infarction (STEMI), our search revealed no literature specific
to a post-cardiac arrest subgroup in whom a spontaneous
circulation has returned. Though relatively contraindicated in
patients with prolonged cardiopulmonary resuscitation,
thrombolysis would not be unreasonable to use in those
patients with electrocardiogram (ECG) evidence of recent
coronary artery occlusion. Clinical and ECG findings,
however, may not predict arterial occlusion, and immediate
angioplasty can improve survival to hospital discharge [22].
Angiography can identify the presence of thrombus-
associated coronary artery occlusion that may be the cause
of cardiac arrest.
Revascularisation may improve survival through myocardial
salvage. Bendz and colleagues [18] showed that OOHCA
patients with ECG-confirmed STEMI receiving primary angio-
plasty had a survival rate comparable to a control non-cardiac
arrest STEMI group 2 years after hospital discharge.
However, the study included only patients with an arrest-to-
resuscitation time of less than 10 minutes and thus may have
enrolled only those with a higher probability of survival.
Unfortunately, no data on the incidence of arrhythmia post-
revascularisation were given [18].
Retrospective case series have identified coronary artery
bypass grafting (CABG) as a tool in reducing the incidence
of recurrent arrest and prolonging survival after STEMI
OOHCA [23,24]. Data extracted from the Antiarrhythmics
Versus Implantable Defibrillators (AVID) study showed, in
281 patients (presenting with ventricular arrhythmias) who
received CABG, an improvement in 5-year survival
independent of ICD implantation [25]. A retrospective
observational study of 50 post-cardiac arrest patients
identified a reduction in inducible arrhythmias following
CABG; VF was no longer inducible in all 11 patients who had
inducible VF pre-operatively. In contrast, 80% of patients with
inducible VT pre-operatively still had the arrhythmia following
surgery [26]. Ventricular arrhythmia cardiac arrest survivors
with coronary artery disease and non-inducible arrhythmias
had a 100% survival rate (n = 18) over a 4-year follow-up
(range, 1 to 48 months) compared with 87% (18/80) in
patients not revascularised with inducible arrhythmias [27].
The CABG Patch trial, a prospective study of 900 patients
with a left ventricular ejection fraction (LVEF) of less than
0.36 and ECG abnormalities scheduled for elective CABG
who were randomly assigned to ICD or standard medical
therapy, found that ICD use conferred no additional survival
benefit to patients at high risk of arrhythmia formation [28]. In
the control limb, the arrhythmia rate was low, implying that
Available online http://ccforum.com/content/11/6/235
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.revascularisation reduces the incidence of arrhythmia
formation and subsequent death. Revascularisation reduces
the incidence of cardiac ischaemia that commonly precedes
potentially fatal ventricular arrhythmias [29,30]. However,
some patients following CABG may still have malignant
arrhythmias. A case series of 23 cardiac arrest survivors
discovered that 43% of patients received at least one ICD
shock (range, 1 to 22 shocks) over a mean follow-up of 34
months. All patients had received CABG for ischaemia and
were non-inducible with programmed stimulation [31].
Not all patients with potentially fatal arrhythmias have
operable coronary artery disease. Therefore, revascularisation
as a tool for arrhythmia management can be useful only in a
specific cohort of patients. Though not specifically described
in the post-cardiac arrest population, beta-blockers, aspirin,
and statins have all been shown to prolong survival in patients
with ischaemic heart disease. Thus, current guidelines
produced by a task force representing the American Heart
Association and American College of Cardiology state that
patients with peri-MI ventricular arrhythmias in whom
ischaemia is fully reversed do not require an ICD and that
those with ischaemia not fully reversible should receive an
ICD [32].
Thus, revascularisation appears to improve survival through a
reduction in malignant arrhythmias and, potentially, myo-
cardial salvage. There is currently no evidence supporting the
use of thrombolysis in patients post-arrest without electro-
graphic evidence of acute MI. The literature suggests that
there should be a greater use of early angiography and
electrophysiological testing to identify the presence of
reversible ischaemia and the need for revascularisation or the
use of ICD or antiarrhythmic agents. Although there is more
evidence supporting the use of CABG compared with
percutaneous angioplasty, this may be purely historical and
requires further assessment.
Pharmacological and electrical rhythm stabilisation
Pharmacological and electrical methods often are employed
to prevent the recurrence of arrhythmias, with amiodarone
commonly used for arrhythmia prevention [33]. Retrospective
studies of antiarrhythmic drug use after cardiac arrest have
produced conflicting results [34-37]. The CASCADE
(Cardiac Arrest in Seattle: Conventional Versus Amiodarone
Drug Evaluation) study, a randomised multi-centre study of
228 patients post-VF confirmed cardiac arrest with electro-
physiological evidence of an increased risk of further
episodes, showed amiodarone to be superior to other
antiarrhythmic agents at preventing VF arrests, sudden
cardiac arrest, and ICD triggering episodes at 2, 5, and
6 years after the event [38]. However, the increasing use of
ICDs may have a role in reducing long-term mortality,
especially the high mortality rate seen in the first year after
hospital discharge. Several observational studies have seen
an increase in long-term survival and an increase in ICD use
over the same time frames [10,13,14]. Pell and colleagues
[5] estimated a 5-year mortality reduction if all patients fitting
the criteria for ICDs had received them.
The role of ICDs for ventricular arrhythmia management has
been proven in randomised controlled trials. The Multicenter
Unsustained Tachycardia Trial (MUSTT) prospectively ran-
domly assigned 754 patients (with coronary artery disease,
an LVEF of less than 40%, and spontaneous unsustained
tachycardia or sustained tachycardia on electrophysiological
manipulation) to either antiarrhythmic therapy (pharmaco-
logical or electrical) or conventional medical therapy (beta-
blockers/ACE/diuretics/aspirin). The mean follow-up was 39
months. A 7% absolute risk reduction of death from arrhyth-
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Table 2
Scottish Intercollegiate Guideline Network: levels of evidence [151]
Level of evidence Evidence required
1++ High-quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1– Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High-quality systematic reviews of case-control or cohort studies
High-quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that 
the relationship is causal
2+ Well-conducted case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability 
that the relationship is causal
2– Case-control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is 
not causal
3 Non-analytic studies (for example, case reports and case series)
4 Expert opinionmia or cardiac arrest was found in those randomly assigned
to antiarrhythmic therapy. This was solely due to the use of
ICDs and not pharmacological therapy [39]. Patients with
ICDs not only had fewer cardiac arrests and arrhythmias, but
also had improved survival every year for 5 years after
enrolment compared with other study patients. Of those
assigned to pharmacological agents, only 10% received
amiodarone compared with more than 40% receiving class I
antiarrhythmic agents. Whether this may have biased the
result is uncertain [40]. The MADIT I (Multicenter Automatic
Defibrillator Implantation I) study, a prospective randomised
trial of 196 patients with inclusion criteria similar to those of
the MUSTT study, identified a statistically significant positive
outcome for those assigned to ICDs compared with
pharmacological agents (54% 2-year reduction in all-cause
mortality). The main antiarrhythmic agent in this study was
amiodarone [41,42].
Specific to post-cardiac arrest patients, a meta-analysis of
three randomised controlled trials (AVID, Canadian
Implantable Defibrillator Study [CIDS], and Cardiac Arrest
Study Hamburg [CASH]) investigated the role of ICDs versus
amiodarone in ventricular arrhythmia reduction and mortality
[43-47]. The meta-analysis concluded that there was a 27%
reduction in the relative risk of dying (absolute reduction of
3.5% per year) and this was due almost entirely to a 50%
reduction in arrhythmic death. The three studies enrolled
patients with ventricular arrhythmias, the majority after cardiac
arrest. The combined mean follow-up period was 2.3 (± 1.89
standard deviation) years. Patients with an LVEF of less than
35% benefited significantly more from an ICD than those with
a greater ejection fraction. The prospective multi-centre
CASH study of 288 patients post-cardiac arrest (secondary
to sustained ventricular arrhythmias) randomly assigned
patients to ICD or amiodarone or metoprolol. The minimum
follow-up period was 2 years, with a mean of 57 ± 34 months.
Overall mortality rates from all causes were 36.4% in the ICD
arm and 44.4% in the antiarrhythmic arm (23% reduction).
Although this was not statistically significant, there were fewer
sudden deaths in the ICD group; 73% had evidence of
coronary artery disease, raising the question of whether
revascularisation would have altered the results.
The AVID study was the only one to show a statistically
significant difference. The AVID population consisted of
patients with documented VF or symptomatic VT, whereas
the CASH and CIDS studies were confined to cardiac arrest
survivors. More than a third of the AVID study patients were
not post-cardiac arrest. There were other significant
differences in the inclusion criteria between the three studies.
The AVID study, with more than 500 patients in each limb,
identified a superior all-cause and arrhythmic death reduction
(all-cause deaths 16.5% versus 10%, arrhythmic deaths
7.4% versus 3%, and 27% reduction in all-cause mortality at
2 years). The follow-up period was only 1.5 years as a
statistically significant benefit of ICDs led to the early
termination of the study. The longest follow-up period
described has been 11 years. Patients reported were a
subgroup of those enrolled from one centre into the CIDS
study. Total mortality was 5.5% per year in the amiodarone
group compared with 2.8% in the ICD group. Patients
receiving amiodarone had not only a statistically higher
mortality but also a greater recurrence of arrhythmias and
drug side effects [47]. Similar results have been reported by
Hennersdorf and colleagues [48] in Düsseldorf, Germany.
This echoes a previous smaller study with a mean follow-up
of 27 months [49].
A two-centre retrospective cohort study (Massachusetts/Los
Angeles) of 331 OOHCA patients discharged from the
hospital identified that 71% had coronary artery disease and
reduced ventricular function, 97.6% had a ventricular
arrhythmia as the cause of their arrest, and median follow-up
was 35 months (range, 1 to 151 months). More deaths (34.3%
versus 19.3%) and sudden cardiac deaths (14.4% versus
3.3%) occurred in patients without an ICD. Multivariate
analysis identified predictors of cardiac mortality as an LVEF
of less than 0.4, absence of ICD, and the presence of
inducible VT before hospital discharge. Patients with ICDs
had a lower mean follow-up period and less coronary
disease, which may have influenced the overall outcome [50].
A retrospective study of 194 survivors of OOHCA with no
significant inducible arrhythmias on electrophysiological
testing identified that patients receiving an ICD had a lower
incidence of sudden cardiac death. However, there was no
change in overall mortality compared with those without an
ICD. Patients with an ICD were younger and had significantly
less coronary artery disease, which may have biased the
results [51]. A prospective study of 204 patients post-cardiac
arrest identified a significant reduction in mortality in patients
(with inducible tachycardia) receiving ICD compared with
those receiving antiarrhythmic agents. The mean follow-up
period was 57 months [48]. ICDs in conjunction with additional
antiarrhythmic agents have been compared with ICD therapy
alone. A prospective multi-centre study randomly assigned
patients with ICDs to amiodarone and beta-blocker, sotalol,
or a beta-blocker (metoprolol, carvedilol, or bisoprolol) for 1
year. Patients had to have sustained VT, VF inducible VT or
VF by programmed ventricular stimulation, or cardiac arrest
(and an LVEF of less than 40%) as the reason for ICD
insertion. The main outcome measure was ICD shock for any
reason. Shocks occurred in 38.5% assigned to beta-blocker
alone, 24.3% in the sotolol group, and 10.3% in the
amiodarone and beta-blocker group. Given that ICD shocks
are painful, this may help to improve patient acceptance of
the devices [52].
Much of the evidence for arrhythmia management and its
influence on long-term survival originated from patients with
proven arrhythmias who were not specifically post-cardiac
arrest. Although there is less evidence available for post-
cardiac arrest patients, the studies available are prospective,
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are superior to pharmacological agents alone at preventing
further arrhythmias and prolonging survival. Although ICDs
prevent sudden death, they add a considerable cost impact
to patient care and produce painful shocks. Patient selection
and, possibly, combined pharmacological therapy are
important factors when looking to provide cost-effectiveness.
Revascularisation remains an option for a specific subgroup
of patients with reversible ischaemia.
Cardiac dysfunction post-arrest
Negovsky [53] described a multi-organ dysfunction syndrome
that affects cardiovascular, neurological, pulmonary, and
metabolic systems and that occurs after ROSC. Post-
resuscitation myocardial dysfunction is now recognised as a
separate entity from myocardial stunning secondary to
coronary artery occlusion and may lead to a worse prognosis
[54]. Patients often require inotropic support following a
cardiac arrest for depressed ventricular function; this often
reverses within 24 to 48 hours [55-57]. In animal studies,
global myocardial stunning has been linked to ischaemia
duration, the number and type of defibrillation shocks, and the
total dose of epinephrine used during resuscitation [58-63].
A prospective study of transthoracic echocardiography
performed 6 hours after ROSC following OOHCA found, on
multiple regression analysis, prolonged cardiopulmonary
resuscitation, defibrillation, and high-dose epinephrine (greater
than 5 mg) to be associated with poor left ventricular (LV)
systolic function. Patients with an LVEF of less than 40% had
a higher mortality over the course of 60 days after the event
and significantly worse neurological outcomes (as assessed
by Cerebral Performance Category [CPC] scores, see
Table 3). Impaired LV diastolic function, assessed by
isovolumetric relaxation times, was associated with non-
VF/VT cardiac arrests and was an independent predictor of a
poor outcome [64]. Attempts to correct the dysfunction
mechanically and pharmacologically may lead to improved
long-term outcomes. As yet, however, there is little robust
evidence on which to base specific recommendations [65-68].
Therapeutic hypothermia after cardiac arrest
Neurological injury accounts for a high proportion of early
mortality in hospital and within the first year after discharge.
Mechanisms described include reperfusion injury, production
of free radicals and excitotoxic agents, the activation of
degenerative enzymes, and reduced cerebral blood flow after
arrest [69-73]. Animal studies have shown that mild
therapeutic hypothermia (34°C to 36°C) can limit the degree
of brain injury by minimising the above processes [74,75].
Some therapeutic benefit is lost if there is a delay (greater
than 15 minutes after ROSC) in instituting hypothermia [76].
Human studies have shown that moderate therapeutic
hypothermia (MTH) reduces hospital mortality and improves
neurological outcome [69,77-80]. Bernard and colleagues
[69] randomly assigned 77 post-OOH VF patients to
normothermic or MTH (33°C) therapy. Survival to hospital
discharge was improved in the MTH group (49% versus
33%) with higher Overall Performance Category (OPC)
scores [69] (Table 3). The Hypothermia After Cardiac Arrest
Study Group randomly assigned 275 witnessed VF/VT arrest
patients to either maintenance of normothermia or MTH
(32°C to 34°C) for 24 hours after arrest. Survival at 6 months
was higher in the hypothermic group (59%) compared with
the normothermic group (45%), with less neurological injury
as assessed by CPC scores. Fifty-five percent of all patients
in the treatment limb demonstrated a favourable neurological
outcome (CPC 1 to 2) at 6 months compared with 39% in
the control limb [79]. A subsequent meta-analysis of
therapeutic hypothermia in post-VF arrest patients found that
the number needed to treat to prevent one unfavourable
neurological outcome was 6 (confidence interval, 4 to 13).
Although the results are consistent, key differences between
the studies used in the meta-analysis include: presenting
rhythm, method of cooling, time taken to reach target
temperature and duration of hypothermia [81]. To our
knowledge, there have been no follow-up studies of long-term
(greater than 1 year) neurological outcome of patients treated
with post-arrest hypothermia.
Despite the strict inclusion criteria, which may have led to
enrolment bias, similar findings have been described in other
studies [69,71,78,82]. Hypothermia has now been recom-
mended by ILCOR and adopted into resuscitation guidelines
as part of the ‘chain of survival’. Although the evidence to date
has been primarily from VF OOHCA, ILCOR recommend that
it be considered a treatment option for non-VF OOHCA [83].
Adopting therapeutic hypothermia as routine practice,
however, has not occurred in some regions. Reasons given
include technical difficulty and a perceived lack of evidence
[84-87]. Although the evidence to date has been directed at
improvements at 6 months to 1 year, it is reasonable to
presume a long-term neurological benefit, but further follow-up
studies are required to validate this statement.
Glycaemic control
Glycaemic control (80 to 110 mg/dL) in a critically ill popu-
lation may provide short- and long-term survival benefits and
is recommended in the management of patients with sepsis.
Though an area of controversy, reducing the incidence of
infection appears to account for much of the observed
benefit [88,89]. Van den Berghe and colleagues [90]
identified mortality benefit in critically ill medical patients
managed with strict glycaemic control for a minimum of
3 days. The majority of OOHCA patients would fulfil both
criteria and therefore may benefit [90]. Studies examining
patients with brain ‘injuries’, however, are not conclusive.
High mean glucose levels in patients with subarachnoid
haemorrhage are associated with a poor neurological
outcome and increased mortality. The Glucose Insulin in
Stroke Trial, which used glucose/insulin/potassium infusions
for 24 hours after admission to maintain serum glucose
Critical Care    Vol 11 No 6 Arawwawala and Brett
Page 8 of 17
(page number not for citation purposes)between 4 and 7 mmol/L, identified no mortality benefit. This
study was underpowered due to slow recruitment [91-93].
The role of glucose control after OOHCA has been difficult to
establish due to confounding factors (for example, time to
ROSC) [94,95]. A prospective study of 145 patients admitted
following ROSC from a witnessed VF arrest examined the
association of glucose levels in neurological outcome.
Patients receiving insulin or with a history of diabetes were
excluded from the study. A significantly better neurological
outcome (as assessed by CPC scores) at 6 months was
identified in patients with lower median 24-hour glucose
levels (146 ± 39 mg/dL interquartile range) compared with
those with higher levels (184 ± 88 mg/dL) even after
controlling for duration of arrest and lactate levels [96]. A
retrospective observational study of 461 OOHCA patients
identified, by multivariate analysis, that a glucose level of
greater than 10.6 mmol/L within the first 24 hours after
admission was associated with significantly higher hospital
mortality [97]. A retrospective study of 98 patients identified
mean blood glucose as being an independent predictor of
survival at 6 months [98]. Whether glycaemic control confers
longer survival and neurological benefits is unclear. High
glucose levels may be a surrogate marker for the severity of
brain injury incurred, reflecting the release of stress hormones
(for example, cortisol, glucagon, and epinephrine). A study
randomly assigning survivors of OOHCA to tight glycaemic
control or no glucose control would, given the current levels
of evidence for glycaemic control in critical care studies, be
unethical. A sensible approach would be to prevent
hyperglycaemia following OOHCA.
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Table 3
Scoring system
Scoring system Description
EQ-5D Five questions on mobility, self-care, everyday activities, pain, and state of mind, each with three possible answers. 
Total score: 0 to 100. The higher the score, the better the quality of life.
RAND 36 36 questions/statements on physical and emotional health with two to six choices for each question.
15D 15 dimensions with five levels that describe state of health. Patient chooses which best describes their state.
Cerebral Performance  CPC 1: Conscious. Alert and able to work and lead a normal life. May have minor psychological or neurological deficits.
Category (CPC) CPC 2: Moderate cerebral disability. Conscious. Sufficient cerebral function for part-time work in sheltered environment 
or independent activities of daily life. May have hemiplegia, seizures, ataxia, dysarthria, or permanent memory or mental 
changes.
CPC 3: Severe cerebral disability. Conscious. Dependent on others for daily support because of impaired brain function.
CPC 4: Coma, vegetative state.
CPC 5: Death. Certified brain dead or dead by traditional criteria.
Overall Performance  OPC 1: Healthy, alert, capable of normal life. Good cerebral performance (CPC 1) plus no or only mild functional 
Category (OPC) disability from non-cerebral organ system abnormalities.
OPC 2: Moderate overall disability. Conscious. Moderate cerebral disability alone (CPC 2) or moderate disability from 
non-cerebral system dysfunction alone or both. Performs independent activities of daily life. May be able to work part-time 
in sheltered environment but disabled for competitive work.
OPC 3: Severe overall disability. Conscious. Severe cerebral disability alone or severe disability from non-cerebral organ 
system dysfunction alone or both. Dependent on others for daily support.
OPC 4: Same as CPC 4.
OPC 5: Same as CPC 5.
Activities of Daily  Personal ADLs assess bathing, dressing, toilet visit, mobility, continence, and eating. Instrumental ADLs assess cleaning, 
Living (ADLs) shopping, cooking, and transportation.
Functional  An 18-point scale scoring from 1 to 7, with 7 being complete independence. Outcomes measured include self-care, 
Independence  sphincter control, transfers, locomotion, communication, and social cognition.
Measure (FIM™)
Symptom Checklist  A 90-item self-report test designed to reflect psychological symptom patterns within the last 7 days.
90 Revised score
Impact of Event Scale A 15-point self-report questionnaire designed to assess current subjective stress for any specific life event.
Post-traumatic  A 49-point self-report-style questionnaire aimed at assisting with the diagnosis of post-traumatic stress disorder.
Diagnostic Scale
MMS A 30 point scale. Results in the range 0-23 indicate disturbance of cognition. Fields assessed are: Orientation, 
registration, attention and calculation, recall, language
Hospital Anxiety and  Seven questions for anxiety and seven questions for depression with a choice of four answers for each. Scores from 0 to 
Depression Scale 3 for each question, depending on answer given. The higher the total score, the more likely it is that affective symptoms 
are present.Anticonvulsant prophylaxis, thrombolysis, and
neurological outcome
Seizure activity after cardiac arrest is common, with
observational studies identifying an incidence of up to 36%
[99,100]. It is associated with a poor neurological outcome.
However, the presence of seizure activity is likely to be the
effect of significant cerebral injury. Small animal studies have
described a reduction in the neuronal damage after cardiac
arrest with lamotrogine and fosphenytoin [101,102]. There
are, to date, no human studies examining whether anti-
convulsant therapy affects patient outcome in this context.
Small animal studies have demonstrated that peri-arrest
thrombolysis can improve cerebral microcirculation flow and
electroencephalogram readings immediately after ROSC
[103,104]. To date, there are no human studies or case
reports of thrombolysis being used after ROSC to improve
neurological outcome. Given the level of available evidence,
no recommendation can be made for the routine use of
thrombolysis or prophylactic anticonvulsant drugs.
Nishizawa and Kudoh [105] studied eight patients after
OOHCA and discovered jugular bulb venous blood oxygen
saturation altered in direct proportion to changes in mean
arterial pressure. Impairment of cerebral autoregulation may
be due to cerebral ischaemia accompanying cardiac arrest
[105]. Similar results were obtained by Sundgreen and
colleagues [106], identifying either a loss or right shift in
cerebral autoregulation. Maintaining an appropriate mean
arterial pressure may lead to less secondary brain injury.
Although these are areas of considerable interest which may
provide potential therapeutic avenues, recommendations
cannot be made without further research.
Neurocognitive and functional outcome:
effects on survivors and families
Gross neurological outcome
When assessing how successful a resuscitation attempt has
been, the initial Utstein recommendations focussed on survival
at hospital discharge, with function assessed by CPC and
OPC at discharge [107-109]. As up to 90% of hospital
mortality following OOHCA is attributed to brain injury, this
seems an appropriate outcome measure [110].
In Olmstead County, of patients who experienced a VF
OOHCA, 145 (72%) patients were admitted alive, 79 (54%)
survived to hospital discharge, 75 patients discharged had an
OPC score of 1, and 5 patients discharged had a score of 2
(Table 3). Five patients were transferred to a nursing home
with an OPC score of 3 to 4 [21]. Engdahl and colleagues
[14] found that fewer patients were being discharged home
with a CPC score of 1 or 2 over a 20-year period (1981 to
1991, 78%; 1991 to 1998, 63%) and more patients were
being discharged to nursing homes and rehabilitation clinics.
Such differences may reflect the study populations and
community services available. A cause for the increase in
patients requiring long-term care may be advances in peri-
arrest management, with more patients surviving with what,
historically, would have been unsurvivable brain injuries.
Importantly, gross neurological outcome may improve with
time. Among patients who had a CPC score of 2 at
discharge, 77% improved to a CPC score of 1 one year later.
Among patients with a CPC score of 3 at discharge, 25%
improved to a CPC score of 2 and 4% to a CPC score of 1
one year later [111].
Mortality data give no indication of whether an individual
returns to any degree of normal neurological function, and
CPC/OPC, as somewhat gross measures, tend not to
correlate with QOL as judged by questionnaires and
structured interviews. Hsu and colleagues [112] studied 35
patients at an average of 7 months after arrest and found that
CPC correlated poorly with QOL. A CPC score of 1 on
discharge had a sensitivity of 78%, a specificity of 43%, a
positive predictive value of 64%, and a negative predictive
value of 60% for a QOL that was the same as or better than
before the cardiac arrest [112]. Recent recommended
guidelines (from participants of the Utstein Consensus
Symposium) for research into in-hospital post-resuscitation
care suggest the use of QOL markers as a measure of the
effectiveness of care as well as outcome [113]. Three QOL
scales are now recommended. These are the EQ-5D, the
RAND 36, and the 15D [114-116] (Table 3).
Functional outcome and quality of life
Functional assessment is often made using activities of daily
living (ADLs). Two different scales have been described:
personal ADL (P-ADL) and instrumental ADL (I-ADL)
(Table 3) [117,118]. Survivors of cardiac arrest frequently
remain dependent on others for most activities. A
prospective cohort study of patients after OOHCA examined
ADLs 1 year after cardiac arrest, reporting that 5/26 patients
remained dependent [119]. A small retrospective study with
an average follow-up of 25 months found that P-ADL was a
problem for 3/20 patients and that 7/20 patients were
dependent for I-ADLs [120]. Grosvasser and colleagues
[121], using a similar scoring system, found that 17/31
patients were dependent when followed up at least 3 years
after the event. Lundgren-Nilsson and colleagues [110]
assessed ADL using the Functional Independence Measure
(FIM™) and the Instrumental Activity Measure (Table 3). They
found that 61% were dependent for motor performance and
65% for social cognitive areas when assessed within
2 weeks of their cardiac arrest. The level of dependence fell
at 45 days after the event to 43% (motor) and 56% (social
cognitive) with no significant improvement between 45 days
and 1 year [110].
Another marker of recovery often used is a return to pre-
arrest social activities, including employment. The study of
Pußwald and colleagues [122] of 12 survivors at a median
period of 25 months after hospital discharge found that none
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[121] found that only 1 of 31 survivors was back to work
3 years after the cardiac arrest. A retrospective study from
San Francisco, CA, USA, found that, of 61 survivors, 36 had
been in employment prior to their cardiac arrest. At 6 months,
this figure had fallen to 26 and to 16 at 1 year. The largest fall
was in those in full-time employment (46% to 18% at 1 year).
The mean age of this group was 48 years. The main reasons
given for not returning to work were the occurrence of
symptoms with exercise, impairment of intellectual function,
and approaching retirement age [123]. These findings are
similar to those of earlier studies [124,125].
Granja and colleagues [126] used the EQ-5D to assess
health-related QOL in 19 survivors at 6 months. Eight were
working and six of these had returned to their previous level
of activity. Eleven were already retired, with seven returning to
previous levels of activity. Those assessed had a ‘good’ QOL.
No significant differences were found when compared with a
general critical care control group [126]. A retrospective
observational study of OOHCA patients in Rotterdam, The
Netherlands, found that 109 (83%) hospital survivors returned
questionnaires and had a mean EQ-5D visual analogue scale
score of 85/100, representing a good QOL [127]. Thus, the
above studies show that, although CPC and OPC scores are
often used, they may be insensitive and do not truly reflect
functional status.
Memory and cognitive dysfunction
Cognitive impairment is common after cardiac arrest. A study
of 25 patients identified that 72% of patients had mild to
severe impairment in at least one cognitive area at hospital
discharge, with memory being the most common deficit; time
to post-arrest wakening was most predictive of longer-term
cognitive outcome [128]. A retrospective study of 12 patients
with anoxic injury of cardiac origin assessed a median of
25 months after injury found that all had evidence of impair-
ment in areas such as memory, orientation, alertness, and
awareness. Three syndromes were identified: severe physical
and intellectual impairment, dementia, and amnesic syndrome.
Extrapolating this evidence is difficult as all patients had
confirmed brain damage and had undergone prolonged
rehabilitation, thus are unlikely to be representative of all
survivors [129]. A prospective randomised study of 68
OOHCA survivors by Roine and colleagues [130] showed
that 48% still had evidence of cognitive impairment at 1 year,
the incidence at 3 months being 60% measured with the
mini-mental state (MMS) scoring system. Using the MMS
scoring system, Sunnerhagen and colleagues [120] found
that persisting cognitive impairment was still present at
2 years after the event, with cognitive impairment occurring in
35% of survivors studied. The better result may reflect
differences in cardiac arrest populations, population sizes, or
length of time since the event. One notable difference
between the two studies was the time from arrest to arrival of
emergency medical services. Arrival times were shorter in the
study of Sunnerhagen and colleagues compared with the
population of Roine and colleagues, suggesting that the
interval from arrest to commencement of cardiopulmonary
resuscitation (and so cerebral perfusion) is important for long-
term neurological outcome. Others have found memory and
concentration to be still impaired 3 to 4 years after the event
compared with control populations [129,131-134]. The
above studies all suggest that cognitive impairment,
especially concentration, is common after cardiac arrest.
Moreover, the studies exclude patients with severe
neurological impairment, thus masking the true proportion of
impaired survivors. Maximal recovery appears to occur early,
with long-term cognitive impairment a real possibility.
Affective disorders
In the early phase after a cardiac arrest, a high prevalence of
anxiety and panic symptoms has been described [135,136].
Anxiety, depression, anger, stress, and confusion are highest
at hospital discharge. A prospective randomised study
examining the effect of nimodipine on neurocognitive
sequelae after cardiac arrest found that 69% of all patients
surviving to 1 year had depressive symptoms when tested
with the Symptom Checklist 90 Revised score (Table 3).
Nimodipine had no effect on the cognitive functions tested
[130]. O’Reilly and colleagues [137] performed a
retrospective case-control study of 27 patients from Scotland
who were enrolled within 18 months of their resuscitation and
assessed with the Hospital Anxiety and Depression Scale
(Table 3). Clinical anxiety and depression were more common
in the post-cardiac arrest group compared with the MI control
group (30% versus 7% and 15% versus 0%, respectively).
Statistical significance was reached only for depression
[137]. Reasons for these discrepancies probably lie in the
different assessment tools used and the variable and
unmeasured level of support and care provided. Whether
these symptoms persist in the long term is unclear. Some
investigators have reported that affective symptoms tend to
decline over the following year, with the greatest reduction
reported at 6 months after discharge [123,138,139].
Post-traumatic stress disorder symptoms
One of the core criteria for developing post-traumatic stress
disorder (PTSD) is the experiencing of an event that was an
actual or perceived threat to life. Serious illness is now
included as such an event in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) [140].
In their case-control study, O’Reilly and colleagues [137]
found that five (19%) cardiac arrest survivors and two (7%)
MI survivors fulfilled DSM-IV criteria for PTSD when assessed
by structured clinical interview, the Impact of Event Scale
(IES), and a self-reporting questionnaire (Post-traumatic
Diagnostic Scale) (Table 3). There was, however, relatively
poor agreement between the interviews and self-report
diagnoses [137]. A similar-sized study from Munich,
Germany, using IES, examined patients 2 to 5 years after the
event and found that 8/21 patients had PTSD symptoms
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anxiety. Patients with PTSD symptoms reported a lack of
confidence in the future and low estimates of their mental and
somatic condition, tending to report more physical symptoms.
Further analysis identified that sedation at illness onset
reduced the risk of developing PTSD by fivefold [131]. The
mean duration of unconsciousness in those sedated was
618 minutes compared with 92 minutes in those not sedated.
The authors speculate that prolonged sedation may inhibit
imprinting of painful and adverse stimuli; also, awakening in a
more controlled environment may generate more positive
emotions.
Neurocognitive and affective disorders in critical illness
Depression, anxiety, and avoidance symptoms are common
among patients discharged from general intensive care units
[141]. In medical intensive care patients, 33% to 78% of
survivors had neurocognitive impairment at 6 months to
1 year. This can still be present 6 years later [142-145].
Suggested mechanisms include hypoxia, hyperglycaemia,
and ischaemia. Sedative and analgesic drugs and sepsis may
also contribute [146]. Many OOHCA patients spend a
significant period of time in a critical care environment. Thus,
cognitive and psychological disorders may be, in part, a
generic consequence of critical illness rather than the
sequelae of the cardiac arrest itself.
Information from qualitative studies
Several qualitative studies have investigated the broader
aspects of patient survival from the perspective of the
individual and family. Dougherty and colleagues [147]
examined this in survivors of OOH VF arrest who then
received an ICD. Thirteen survivors and family members were
followed up over 1 year after hospital discharge. Using
structured questionnaires and interviews, they identified
‘domains of concern’ and the strategies implemented to cope
with these issues. Common areas of concern for partners
were the physical and emotional care of the survivor, finding
time for their own well-being, relationship changes, under-
standing ICDs and dealing with shocks, money worries, and
communicating with health care providers [138,147]. A study
of eight survivors of cardiac arrest with ICDs by Tagney and
colleagues [148] from Bristol, UK, reported similar observa-
tions. They also found that overprotectiveness of families led
to reduced levels of activity and increasing dependence with
subsequent loss of confidence. Survivors had concerns over
altered body image due to the implanted defibrillator and
often concealed  symptoms, emotions, and concerns about
their ICD from their family. Fear of ICD shocks and possible
death may limit physical recovery, including sexual activities
[148]. Dougherty and colleagues [147] and Tagney and
colleagues [148] found that advice given by health care
providers was often technical, with little advice on how to live
with an ICD. Sears and colleagues [149] also found that
health care providers are often less comfortable dealing with
the emotional aspects of ICDs compared with medical issues.
Once the patient is home, strategies are often implemented
by partners to make the transition from hospital to home as
smooth as possible. Actions employed include arranging and
adapting furniture to allow easier use, words of encourage-
ment to help overcome anger and frustration, and increased
activity levels and using games to improve memory deficits
and help with reorientating the survivor to their environment.
Investigators in this field agree that more could be done to
prepare and support families in the longer term after hospital
discharge. The burden of caring for a survivor can also have a
more severe emotional impact. Pußwald and colleagues
[122] found that 6 of 12 family members interviewed were
clinically depressed, stating concerns over loss of employ-
ment in order to be the main carer and financial worries as
being important.
Although the above qualitative studies raise important issues,
the small size of the samples means that the themes
described above may not encompass all the concerns of
post-arrest patients. Furthermore, the literature has concen-
trated on patients post-arrest with ICDs and may not
accurately reflect the general post-arrest population.
Conclusion
Longer-term survival following OOHCA is improving. Post-
resuscitation management has been highlighted in the
European Resuscitation Council guidelines of 2005. The new
‘Chain of Survival’ for surviving cardiac arrest now places
more emphasis on the final link: ‘post-resuscitation care to
restore quality of life’ [150].
Revascularisation, ICDs, and therapeutic hypothermia appear
to have had a considerable impact. Revascularisation and
ICDs reduce mortality in the long term mainly by arrhythmia
management. However, the considerable financial impact of
these interventions means that patient selection is all impor-
tant to ensure cost-effectiveness. The presence of reversible
ischaemia with or without inducible arrhythmia needs to be
identified early on in the post-resuscitation management
phase. There is a strong argument to be made for early angio-
graphy in all post-arrest survivors and electrophysiological
testing for those patients without reversible ischaemia. Based
on the evidence available, angioplasty appears to have a role
to play in revascularisation and its role will become more
defined with further research into this area.
Therapeutic hypothermia improves short-term survival and
gross neurological outcome. However, its impact on longer-
term sequelae has yet to be reported. Although there are
inconsistencies in the methodologies used in the various
studies, the uniformly positive outcomes mean it should be
considered for all cardiac arrest survivors irrespective of the
causative arrhythmia. It is likely that outcomes will improve as
cooling techniques become more sophisticated, allowing for
more rapid and controlled cooling and rewarming.
Critical Care    Vol 11 No 6 Arawwawala and Brett
Page 12 of 17
(page number not for citation purposes)Tight glucose control to date is unproven in OOHCA
survivors. However, the evidence available suggests that it
may be associated with an improved neurological outcome.
Given the recommendations for glycaemic control in the
critically ill population, it would seem sensible to apply these
to post-cardiac arrest patients until further evidence is
available. The potential risk for hypoglycaemia and
exacerbating cerebral injury needs to be taken into account.
Although mortality is a useful clinical tool for assessing
changes in practice, it does not reveal any information about
more subtle outcomes important to the patient and their
families. Functional dependency and neuropsychiatric
sequelae are common and may be due to the initial insult or a
response to the critical illness state. A better understanding
of the patients’ needs after hospital discharge may lead to an
improvement in the level of after-care currently provided. This
can be achieved only by ensuring that the research agenda
include longer-term outcome reporting and that such
reporting be sufficiently sophisticated to encompass a multi-
dimensional assessment of quality of survival, impact on
families, and future health care needs and costs. In simple
terms, producing cohorts of severely damaged survivors is
unlikely to be universally regarded as a success.
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